Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Captafer vs Iron Sulfate for IDA in IBD
NCT02774057Phase 4Unknown
- Sponsor
- American University of Beirut Medical Center
- Start
- Mar 2016
- Primary completion
- Jul 2017
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (2 arms), sponsored by American University of Beirut Medical Center. Primary endpoint: Tolerability to Iron sulfate and Captafer® at 6 weeks. Status: unknown.
Beyond the preview
Go deeper on NCT02774057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02774057.